AbbVie confirms 2026 EPS guidance alongside etentamig Phase 3 gains
AbbVie reported Phase III CERVINO results for etentamig, citing higher ORR, lower progression risk and improved 12-month OS, and confirmed a blood-cancer primary endpoint. The company reaffirmed 2026 EPS guidance.
AbbVie, Inc. (NYSE:ABBV) reported strong Phase III CERVINO results for etentamig, citing higher ORR, lower progression risk and improved 12—month OS. The company said the study met its blood-cancer primary endpoint. AbbVie also confirmed 2026 EPS guidance, added immunology assets and launched SkinMedica Barrier Calming Cream.